Mitomycin-C, 5-fluorouracil, and leucovorin as a salvage therapy in patients with metastatic colorectal adenocarcinoma

Asia-Pacific Journal of Clinical Oncology

Volumn 6, Issue 4, 2010, Pages 286-291

  Kang, Eun Joo ^a   Choi, Yoon Ji ^a   Kim, Jung Seon ^a   Kim, Seung Tae ^a   Park, Kyong Hwa ^a   Choi, In Keun ^a   Oh, Sang Chul ^a   Seo, Jae Hong ^a   Shin, Sang Won ^a   Kim, Jun Suk ^a   Kim, Yeul Hong ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

5 FU; Leucovorin; Mitomycin; Refractory colon cancer

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MITOMYCIN C; OXALIPLATIN;

ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; COLORECTAL CARCINOMA; DRUG DOSE REDUCTION; DRUG FATALITY; FEMALE; FEVER; HEMOLYTIC UREMIC SYNDROME; HUMAN; INFECTION; KIDNEY DISEASE; LIVER DYSFUNCTION; LIVER FUNCTION; MALE; METASTASIS; MUCOSA INFLAMMATION; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SALVAGE THERAPY; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT RESPONSE; WEAKNESS;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; MITOMYCIN; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 78649783656     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/j.1743-7563.2010.01334.x     Document Type: Article

References (25)

1. National Cancer Center. Cancer statistics in Korea. National Cancer Center Cited 13 September 2010.] Available from URL.
2. American Cancer Society. Cancer Facts & Figures. American Cancer Society, Atlanta, GA 2009.
3. Poon MA, O'Connell MJ, Moertel CG etal. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989; 7: 1407-18.
4. Saltz LB, Clarke S, Díaz-Rubio E etal. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013-19.
5. Sanoff HK, Sargent DJ, Campbell ME etal. Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J Clin Oncol 2008; 26: 5721-7.
6. Jin C Yao L, Long J etal. Effect of multiple-phase regional intra-arterial infusion chemotherapy on patients with resectable pancreatic head adenocarcinoma. Chin Med J (Engl) 2009; 122: 284-90.
7. Miyamoto H, Yoshida M, Yamanouchi T etal. [Combination of irinotecan and Mitomycin C as second-line chemotherapy for patients with unresectable advanced or recurrent gastric cancer in clinical practice]. Gan To Kagaku Ryoho 2009; 36: 1293-7.
8. Shen Z, Shen T, Wientjes MG, O'Donnell MA, Au JL. Intravesical treatments of bladder cancer: review. Pharm Res 2008; 25: 1500-10.
9. Kano Y, Suzuki K, Akutsu M etal. Effects of CPT-11 in combination with other anti-cancer agents in culture. Int J Cancer 1992; 50: 604-10.
10. Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 1998; 4: 1013-19.
11. Franchi F, Barone C, Seminara P etal. 5-fluorouracil (FU) and mitomycin C (MMC) in the management of colorectal carcinoma. Part II. In vitro activity of the two drugs in short-term tumor cultures. Med Oncol Tumor Pharmacother 1991; 8: 75-8.
12. Chong G, Dickson JL, Cunningham D etal. Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan. Br J Cancer 2005; 93: 510-14.
13. Lim DH, Park YS, Park BB etal. Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study. Cancer Chemother Pharmacol 2005; 56: 10-14.
14. Vormittag L, Kornek GV, Gruhsmann B etal. UFT/leucovorin and mitomycin C as salvage treatment in patients with advanced colorectal cancer - a retrospective analysis. Anticancer Drugs 2007; 18: 709-12.
15. Park BB, Im YH, Hwang IG etal. Salvage chemotherapy with mitomycin C, ifosfamide, and cisplatin (MIC) for previously treated metastatic or recurrent esophageal squamous cell carcinoma. Invest New Drugs 2008; 26: 387-92.
16. Grothey A, Schmoll HJ. New chemotherapy approaches in colorectal cancer. Curr Opin Oncol 2001; 13: 275-86.
17. Jonker DJ, O'Callaghan CJ, Karapetis CS etal. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007; 357: 2040-8.
18. Cunningham D, Humblet Y, Siena S etal. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-45.
19. Van Cutsem E, Peeters M, Siena S etal. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25: 1658-64.
20. Karapetis CS, Khambata-Ford S, Jonker DJ etal. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757-65.
21. De Roock W, Piessevaux H, De Schutter J etal. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008; 19: 508-15.
22. Lièvre A, Bachet JB, Boige V etal. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008; 26: 374-9.
23. Capdevila J, Ramos FJ, Macarulla T, Elez E, Tabernero J. The role of salvage treatment in advanced colorectal cancer. Crit Rev Oncol Hematol 2009; 71: 53-61.
24. Ziras N, Potamianou A, Varthalitis I etal. Multicenter phase II study of gemcitabine and oxaliplatin (GEMOX) as second-line chemotherapy in colorectal cancer patients pretreated with 5-fluorouracil plus irinotecan. Oncology 2006; 70: 106-14.
25. Bitossi R, Sculli CM, Tampellini M etal. Gemcitabine and protracted 5-fluorouracil infusion as third-line chemotherapy in refractory colorectal cancer patients. Anticancer Res 2008; 28: 3055-60.